Exagen Inc (XGN) Stock Price, Quote & News

Company Profile

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms in...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 760 560 1501

Website: www.exagen.com

Address:

1261 Liberty Way, Suite C, Vista, United States

STACKD0E Aug. 13 at 2:24 PM

$XGN 🙃✨

0 · Reply

Laynester Aug. 6 at 3:00 PM

$XGN Doubled the postion. Set a stop. Good to all.

0 · Reply

GSP Aug. 5 at 10:48 AM

$XGN $GCTK $INHD $FCUV $CYCU

1 · Reply

TNNStockAnalysisNews Aug. 5 at 2:48 AM

Top Gainers — August 4, 2026 $AMIX - +386% — The Day’s Most Explosive Move $MOVE - +53% to $16.46 — The Nvidia Blackwell AI Infrastructure Bet $IBTA - +46% to $35.80 — The Earnings Beat That Rewrites the Story $BLZE - +37.78% to $21.48 — A $335 Million AI Storage Landgrab $XGN - +39% — Diagnostics Company Posts Record Quarter https://truthsandnews.com/markets/top-10-stock-gainers-today-aug-4-2026-amix-move

0 · Reply

ComicBook_Girl Aug. 5 at 1:49 AM

Picked up some XOS today. Cash-rich and the uptrend is strong. Setting up just like last August when they ran over 100%. Put in some bids for PM as well. If $ZJYL dips $2.70's in premarket I'll pick up a few. Open tomorrow could see a nice move. Same with $XGN if it sees low-$6's. Could give good scalps. XOS August 2025 attached.

0 · Reply

topstockalerts Aug. 4 at 9:41 PM

Top Gainers PT2 $IBTA $GCTK $XGN $ENSC $TSAT

0 · Reply

GSP Aug. 4 at 8:58 PM

Your Day Trading Watch List Video for August 5th in About 2 Minutes (con't): $XGN $GCTK $INHD $FCUV $CYCU .

1 · Reply

topstockalerts Aug. 4 at 7:47 PM

Top Gainers .PT2 $TNMG $ENSC $XGN $MED $TSAT

0 · Reply

topstockalerts Aug. 4 at 7:28 PM

Top Gainers PT2 $TNMG $ENSC $XGN $MED $TSAT

0 · Reply

GREENFLOORPURPLEGOLD Aug. 4 at 6:01 PM

$XGN Nice 🤑 🤑 🤑 🤑

0 · Reply

Exagen Transcript: Canaccord Genuity's 46th Annual Growth Conference

2026-08-05T14:24:44.000Z - 11 days ago

Exagen price target raised to $9 from $8 at BTIG

2026-08-05T14:08:45.000Z - 11 days ago

Exagen price target raised to $12 from $8 at B. Riley

2026-08-05T13:58:16.000Z - 11 days ago

Exagen price target raised to $10 from $8 at TD Cowen

2026-08-05T11:27:54.000Z - 11 days ago

Exagen price target raised to $9 from $8 at Canaccord

2026-08-04T13:00:29.000Z - 12 days ago

Exagen raises FY26 revenue view to $72M-$75M from $70M-$73M

2026-08-04T12:55:26.000Z - 12 days ago

Exagen reports Q2 EPS (13c), consensus (17c)

Aug 4, 2026, 8:30 AM EDT - 12 days ago

Exagen Earnings Call Transcript: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 12 days ago

Exagen Earnings release: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 12 days ago

Exagen Slides: Q2 2026

Aug 4, 2026, 8:30 AM EDT - 12 days ago

Exagen Quarterly report: Q2 2026

Aug 4, 2026, 8:00 AM EDT - 12 days ago

Exagen Inc. Reports Second Quarter 2026 Financial Results

Jul 28, 2026, 9:00 AM EDT - 19 days ago

Exagen Inc. to Participate in Upcoming Investor Conference

Jul 21, 2026, 9:00 AM EDT - 26 days ago

Exagen to Announce Second Quarter Financial Results on August 4, 2026

2026-06-24T22:20:10.000Z - 7 weeks ago

Roth starts Exagen at Buy, notes biomarker testing outperformance

2026-06-24T20:30:53.000Z - 7 weeks ago

Exagen initiated with a Buy at Roth Capital

Jun 1, 2026, 9:00 AM EDT - 2 months ago

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

2026-05-12T11:50:22.000Z - 3 months ago

Exagen price target lowered to $8 from $9 at BTIG

2026-05-11T16:09:37.000Z - 3 months ago

Exagen reports Q1 EPS (17c), consensus (25c)

2026-05-11T16:03:49.000Z - 3 months ago

Exagen backs FY26 revenue view $70M-$73M, consensus $71.27M

May 11, 2026, 8:30 AM EDT - 3 months ago

Exagen Earnings Call Transcript: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Exagen Earnings release: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Exagen Quarterly report: Q1 2026

May 11, 2026, 8:30 AM EDT - 3 months ago

Exagen Slides: Q1 2026

May 11, 2026, 8:00 AM EDT - 3 months ago

Exagen Inc. Reports First Quarter 2026 Results

Apr 27, 2026, 9:00 AM EDT - 3 months ago

Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Exagen Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Exagen Proxy statement: Proxy filing

2026-04-20T13:56:34.000Z - 4 months ago

Exagen price target lowered to $8 from $10 at Canaccord

2026-03-11T13:21:32.000Z - 5 months ago

Exagen price target lowered to $10 from $12 at Craig-Hallum

2026-03-11T11:10:32.000Z - 5 months ago

Exagen price target lowered to $10 from $15 at Canaccord

2026-03-11T10:36:24.000Z - 5 months ago

Exagen price target lowered to $10 from $15 at KeyBanc

2026-03-10T19:45:16.000Z - 5 months ago

Exagen price target lowered to $9 from $10 at BTIG

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Exagen Earnings Call Transcript: Q4 2025

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Exagen Annual report: Q4 2025

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Exagen Earnings release: Q4 2025

Mar 10, 2026, 8:30 AM EDT - 5 months ago

Exagen Slides: Q4 2025

2026-03-10T12:12:45.000Z - 5 months ago

Exagen reports Q4 EPS (20c), consensus (19c)

2026-03-10T12:12:08.000Z - 5 months ago

Exagen sees FY26 revenue $70M-$73M, consensus $73.84M

Mar 10, 2026, 8:00 AM EDT - 5 months ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results

Mar 3, 2026, 9:00 AM EST - 5 months ago

Exagen Inc. to Participate in Upcoming Investor Conferences

Feb 24, 2026, 9:00 AM EST - 6 months ago

Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026

2026-02-24T13:44:49.000Z - 6 months ago

Exagen price target lowered to $10 from $13 at TD Cowen

Jan 11, 2026, 3:00 PM EST - 7 months ago

Exagen Inc. Announces Select Preliminary 2025 Financial Results

Nov 11, 2025, 9:00 AM EST - 9 months ago

Exagen Inc. to Participate in Fourth Quarter Investor Conferences

Nov 4, 2025, 8:30 AM EST - 10 months ago

Exagen Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Exagen Quarterly report: Q3 2025

Nov 4, 2025, 8:30 AM EST - 10 months ago

Exagen Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Exagen Inc. Reports Strong Q3 2025 Results

Oct 23, 2025, 9:15 AM EDT - 10 months ago

Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence

Oct 21, 2025, 4:05 PM EDT - 10 months ago

Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025

Aug 6, 2025, 4:05 PM EDT - 1 year ago

Exagen Inc. to Participate in Third Quarter Investor Conferences

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Exagen Earnings Call Transcript: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Exagen Quarterly report: Q2 2025

Jul 29, 2025, 8:30 AM EDT - 1 year ago

Exagen Earnings release: Q2 2025

Jul 29, 2025, 8:00 AM EDT - 1 year ago

Exagen Inc. Reports Strong Q2 2025 Results

Jul 17, 2025, 4:05 PM EDT - 1 year ago

Exagen Inc. Appoints Chas McKhann to Board of Directors

Jul 15, 2025, 4:05 PM EDT - 1 year ago

Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025

Jun 23, 2025, 9:00 AM EDT - 1 year ago

Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

Jun 20, 2025, 8:00 AM EDT - 1 year ago

Exagen Registration statement: Registration Filing

May 9, 2025, 4:05 PM EDT - 1 year ago

Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

May 8, 2025, 8:30 AM EDT - 1 year ago

Exagen Inc. Prices Public Offering of Common Stock

May 7, 2025, 4:05 PM EDT - 1 year ago

Exagen Inc. Announces Proposed Public Offering of Common Stock

May 5, 2025, 8:30 AM EDT - 1 year ago

Exagen Earnings Call Transcript: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

Exagen Quarterly report: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

Exagen Earnings release: Q1 2025

May 5, 2025, 8:00 AM EDT - 1 year ago

Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Exagen Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Exagen Proxy statement: Proxy Filing

Apr 28, 2025, 9:00 AM EDT - 1 year ago

Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors

Apr 21, 2025, 4:05 PM EDT - 1 year ago

Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Exagen Earnings Call Transcript: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Exagen Annual report: Q4 2024

Mar 11, 2025, 8:30 AM EDT - 1 year ago

Exagen Earnings release: Q4 2024

Mar 11, 2025, 8:00 AM EDT - 1 year ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

Mar 5, 2025, 1:10 PM EST - 1 year ago

Exagen Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 25, 2025, 4:05 PM EST - 1 year ago

Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025

Jan 12, 2025, 12:00 PM EST - 1 year ago

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Dec 12, 2024, 9:00 AM EST - 1 year ago

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Nov 14, 2024, 4:30 PM EST - 1 year ago

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Nov 12, 2024, 8:30 AM EST - 1 year ago

Exagen Earnings Call Transcript: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Exagen Quarterly report: Q3 2024

Nov 12, 2024, 8:30 AM EST - 1 year ago

Exagen Earnings release: Q3 2024

Oct 21, 2024, 4:05 PM EDT - 1 year ago

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Sep 4, 2024, 4:05 PM EDT - 2 years ago

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

Aug 14, 2024, 2:30 PM EDT - 2 years ago

Exagen Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Exagen Earnings Call Transcript: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Exagen Quarterly report: Q2 2024

Aug 5, 2024, 8:30 AM EDT - 2 years ago

Exagen Earnings release: Q2 2024

Aug 2, 2024, 9:00 AM EDT - 2 years ago

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 1, 2024, 9:00 AM EDT - 2 years ago

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

Jul 22, 2024, 9:00 AM EDT - 2 years ago

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

May 13, 2024, 8:30 AM EDT - 2 years ago

Exagen Earnings Call Transcript: Q1 2024

May 13, 2024, 8:30 AM EDT - 2 years ago

Exagen Quarterly report: Q1 2024

May 13, 2024, 8:30 AM EDT - 2 years ago

Exagen Earnings release: Q1 2024

May 13, 2024, 8:00 AM EDT - 2 years ago

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

Apr 30, 2024, 4:05 PM EDT - 2 years ago

Exagen to Announce First Quarter 2024 Results on May 13, 2024

Apr 26, 2024, 8:30 AM EDT - 2 years ago

Exagen Inc. Announces Changes to the Board of Directors

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Exagen Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Exagen Proxy statement: Proxy Filing

Mar 18, 2024, 8:30 AM EDT - 2 years ago

Exagen Earnings Call Transcript: Q4 2023

Mar 18, 2024, 8:30 AM EDT - 2 years ago

Exagen Annual report: Q4 2023

Mar 18, 2024, 8:30 AM EDT - 2 years ago

Exagen Earnings release: Q4 2023

Mar 18, 2024, 8:00 AM EDT - 2 years ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

Mar 8, 2024, 9:00 AM EST - 2 years ago

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 7, 2024, 4:05 PM EST - 2 years ago

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Jan 7, 2024, 12:00 PM EST - 2 years ago

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Nov 27, 2023, 7:00 AM EST - 2 years ago

Exagen Registration statement: Registration Filing

Nov 17, 2023, 7:00 AM EST - 2 years ago

Exagen Registration statement: Registration Filing

Nov 13, 2023, 4:30 PM EST - 2 years ago

Exagen Earnings Call Transcript: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

Exagen Quarterly report: Q3 2023

Nov 13, 2023, 4:30 PM EST - 2 years ago

Exagen Earnings release: Q3 2023

Nov 13, 2023, 4:05 PM EST - 2 years ago

Exagen Inc. Reports Strong Third Quarter 2023 Results

Nov 9, 2023, 4:05 PM EST - 3 years ago

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

Oct 30, 2023, 4:05 PM EDT - 3 years ago

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

Sep 28, 2023, 4:05 PM EDT - 3 years ago

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

Sep 12, 2023, 4:05 PM EDT - 3 years ago

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 7, 2023, 8:30 AM EDT - 3 years ago

Exagen Earnings Call Transcript: Q2 2023

Aug 7, 2023, 8:30 AM EDT - 3 years ago

Exagen Quarterly report: Q2 2023

Aug 7, 2023, 8:30 AM EDT - 3 years ago

Exagen Earnings release: Q2 2023

Aug 7, 2023, 8:00 AM EDT - 3 years ago

Exagen Inc. Reports Strong Second Quarter 2023 Results

Jul 26, 2023, 4:05 PM EDT - 3 years ago

Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Jul 25, 2023, 4:05 PM EDT - 3 years ago

Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023

STACKD0E Aug. 13 at 2:24 PM

$XGN 🙃✨

0 · Reply

Laynester Aug. 6 at 3:00 PM

$XGN Doubled the postion. Set a stop. Good to all.

0 · Reply

GSP Aug. 5 at 10:48 AM

$XGN $GCTK $INHD $FCUV $CYCU

1 · Reply

TNNStockAnalysisNews Aug. 5 at 2:48 AM

0 · Reply

ComicBook_Girl Aug. 5 at 1:49 AM

0 · Reply

topstockalerts Aug. 4 at 9:41 PM

Top Gainers PT2 $IBTA $GCTK $XGN $ENSC $TSAT

0 · Reply

GSP Aug. 4 at 8:58 PM

Your Day Trading Watch List Video for August 5th in About 2 Minutes (con't): $XGN $GCTK $INHD $FCUV $CYCU .

1 · Reply

topstockalerts Aug. 4 at 7:47 PM

Top Gainers .PT2 $TNMG $ENSC $XGN $MED $TSAT

0 · Reply

topstockalerts Aug. 4 at 7:28 PM

Top Gainers PT2 $TNMG $ENSC $XGN $MED $TSAT

0 · Reply

GREENFLOORPURPLEGOLD Aug. 4 at 6:01 PM

$XGN Nice 🤑 🤑 🤑 🤑

0 · Reply

thatoneguywho Aug. 4 at 2:52 PM

$XGN

0 · Reply

AC_TRADER Aug. 4 at 2:45 PM

$XGN nicely hitting overhead lines that I drew.

0 · Reply

AC_TRADER Aug. 4 at 2:43 PM

$XGN some levels are being penetrated. Over 30% since some lines were drawn :)

0 · Reply

topstockalerts Aug. 4 at 2:31 PM

$XGN not bad 🙌

0 · Reply

healthcareguru Aug. 4 at 2:21 PM

$XGN fade this bullsh!t all day…complete nonsense. 👎 Back to $5. $XBI $XLV

0 · Reply

topstockalerts Aug. 4 at 2:13 PM

Top Gainers PT2 $BLZE $IBTA $XGN $ELPW $DXST

0 · Reply

Zackpedia Aug. 4 at 2:10 PM

$XGN Selling time at 6.4 now

0 · Reply

STACKD0E Aug. 4 at 2:05 PM

$XGN 👁️

0 · Reply

s3mi Aug. 4 at 1:51 PM

$XGN $ADGM

0 · Reply

s3mi Aug. 4 at 1:36 PM

$XGN $AMIX

0 · Reply

Stock_Catcher Aug. 4 at 1:34 PM

$FCUV mentioned Bounce Angle earlier Great move, $AMIX halted up, $TNMG almost 150% ,$ONDS ripping face $XGN new high of day

0 · Reply

EarningsInsider Aug. 4 at 1:30 PM

https://www.marketbeat.com/earnings/reports/2026-8-4-exagen-inc-stock/ $XGN Exagen Earnings Transcript

0 · Reply

Market Cap	161.34M
Revenue (ttm)	66.58M
Net Income (ttm)	-19.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-29.96%
Debt to Equity Ratio	1.87

Volume	154,200
Avg Vol	306,468
Day's Range	N/A - N/A
Shares Out	24.23M
Stochastic %K	68%
Beta	2.05
Analysts	Strong Sell
Price Target	$9.86